Actively Recruiting
Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease
Led by Tianjin Medical University · Updated on 2025-04-30
500
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the potential usefulness of 11C/18F-HED positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.
CONDITIONS
Official Title
Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors supported by MRI, CT, tumor markers, or pathology reports
- Patients scheduled to undergo HED PET/CT scan
- Patients able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Patients who are pregnant
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
H
Haonan Yu, MD
CONTACT
Q
Qiusong Chen, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here